COVID-19 in a patient with idiopathic pulmonary fibrosis successfully treated with Ruxolitinib

Caradec, E.; Mouren, D.; Zrounba, M.; Blandin, C.; Ivanoff, S. S.; Levy, Virginia; Brillet, Pierre-Yves; Nunès, Hilario; Uzunhan, Y.

doi:10.1016/j.resmer.2020.100799

Cited by 3 publications

(3 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Induced expression of JAK2 worsens diabetic kidney disease (DKD) in experimental mice [ 117 ], and the JAK1/JAK2 inhibitor baricitinib is highly effective in DKD [ 118 ]. The JAK2 inhibitor fedratinib has been reported to reduce mortality from COVID-19 [ 119 ] and ruxolitinib (a tyrosine kinase inhibitor) inhibits viral infection by inhibition of JAK1 and JAK2 and other JAK inhibitors can block cytokine release associated with COVID-19-induced cytokine storm [ 120 ]. Ruxolitinib is under clinical investigation to evaluate COVID-19-associated lung injury [ 121 ], and another JAK2 inhibitor, nintedanib, is being evaluated for SARS-CoV-2-induced pulmonary fibrosis [ 122 ].…”

Section: Discussionmentioning

confidence: 99%

Predicting COVID-19—Comorbidity Pathway Crosstalk-Based Targets and Drugs: Towards Personalized COVID-19 Management

et al. 2021

View full text Add to dashboard Cite

It is well established that pre-existing comorbid conditions such as hypertension, diabetes, obesity, cardiovascular diseases (CVDs), chronic kidney diseases (CKDs), cancers, and chronic obstructive pulmonary disease (COPD) are associated with increased severity and fatality of COVID-19. The increased death from COVID-19 is due to the unavailability of a gold standard therapeutic and, more importantly, the lack of understanding of how the comorbid conditions and COVID-19 interact at the molecular level, so that personalized management strategies can be adopted. Here, using multi-omics data sets and bioinformatics strategy, we identified the pathway crosstalk between COVID-19 and diabetes, hypertension, CVDs, CKDs, and cancers. Further, shared pathways and hub gene-based targets for COVID-19 and its associated specific and combination of comorbid conditions are also predicted towards developing personalized management strategies. The approved drugs for most of these identified targets are also provided towards drug repurposing. Literature supports the involvement of our identified shared pathways in pathogenesis of COVID-19 and development of the specific comorbid condition of interest. Similarly, shared pathways- and hub gene-based targets are also found to have potential implementations in managing COVID-19 patients. However, the identified targets and drugs need further careful evaluation for their repurposing towards personalized treatment of COVID-19 cases having pre-existing specific comorbid conditions we have considered in this analysis. The method applied here may also be helpful in identifying common pathway components and targets in other disease-disease interactions too.

show abstract

Section: Discussionmentioning

confidence: 99%

Predicting COVID-19—Comorbidity Pathway Crosstalk-Based Targets and Drugs: Towards Personalized COVID-19 Management

et al. 2021

View full text Add to dashboard Cite

show abstract

“…As the pandemic of COVID-19 being prolonged, increasing number of cases with chronic ILDs who developed severe respiratory failure by complication with COVID-19 has been reported. We reviewed and summarized them in Table 2 ( 8 , 11 , 12 , 16 – 19 ). The majority of the cases developed respiratory failure with newly-emerged GGOs simultaneously with the diagnosis of COVID-19, therefore treated with combination of antiviral and immunomodulation therapy against COVID-19.…”

Section: Discussionmentioning

confidence: 99%

COVID-19-Triggered Acute Exacerbation of IPF, an Underdiagnosed Clinical Entity With Two-Peaked Respiratory Failure: A Case Report and Literature Review

et al. 2022

View full text Add to dashboard Cite

Because severe coronavirus disease 2019 (COVID-19) affects the respiratory system and develops into respiratory failure, patients with pre-existing chronic lung disorders, such as idiopathic pulmonary fibrosis (IPF), are thought to be at high risk of death. Patients with IPF often suffer from a lethal complication, acute exacerbation (AE), a significant part of which is assumed to be triggered by respiratory viral infection. However, whether mild to moderate COVID-19 can trigger AE in patients with IPF remains unknown. This is the case report of a 60-year-old man with a 4-year history of IPF who successfully recovered from moderate COVID-19 but subsequently developed more severe respiratory failure, which was considered to be a COVID-19-triggered acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF). It is important to be aware of the risk of AE-IPF after COVID-19 and to properly manage this deadly complication of IPF. Recent literature reporting cases with chronic interstitial lung diseases which developed respiratory failure by complications with COVID-19 is also reviewed and discussed.

show abstract

“…Overall, 14 studies (one randomized controlled trial, five observational studies, and eight case reports) investigating the efficacy and safety of ruxolitinib in moderate-severe COVID-19 pneumonia were retrieved [ 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 ]. Main features of included studies are shown in Table 3 .…”

Section: Clinical Evidence With Jak Inhibitors In Covid-19 Settingsmentioning

confidence: 99%

Janus Kinase Inhibitors and Coronavirus Disease (COVID)-19: Rationale, Clinical Evidence and Safety Issues

et al. 2021

View full text Add to dashboard Cite

We are witnessing a paradigm shift in drug development and clinical practice to fight the novel coronavirus disease (COVID-19), and a number of clinical trials have been or are being testing various pharmacological approaches to counteract viral load and its complications such as cytokine storm. However, data on the effectiveness of antiviral and immune therapies are still inconclusive and inconsistent. As compared to other candidate drugs to treat COVID-19, Janus Kinase (JAK) inhibitors, including baricitinib and ruxolitinib, possess key pharmacological features for a potentially successful repurposing: convenient oral administration, favorable pharmacokinetic profile, multifunctional pharmacodynamics by exerting dual anti-inflammatory and anti-viral effects. Baricitinib, originally approved for rheumatoid arthritis, received Emergency Use Authorization in November 2020 by the Food and Drug Administration in combination with remdesivir for the treatment of COVID-19 in hospitalized patients ≥ 2 years old who require supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation. By July 2021, the European Medicines Agency is also expected to issue the opinion on whether or not to extend its use in hospitalised patients from 10 years of age who require supplemental oxygen. Ruxolitinib, approved for myelofibrosis, was prescribed in patients with COVID-19 within an open-label Emergency Expanded Access Plan. This review will address key milestones in the discovery and use of JAK inhibitors in COVID-19, from artificial intelligence to current clinical evidence, including real world experience, and critically appraise emerging safety issues, namely infections, thrombosis, and liver injury. An outlook to ongoing studies (clinicaltrials.gov) and unpublished pharmacovigilance data is also offered.

show abstract

COVID-19 in a patient with idiopathic pulmonary fibrosis successfully treated with Ruxolitinib

Cited by 3 publications

References 5 publications

Predicting COVID-19—Comorbidity Pathway Crosstalk-Based Targets and Drugs: Towards Personalized COVID-19 Management

Predicting COVID-19—Comorbidity Pathway Crosstalk-Based Targets and Drugs: Towards Personalized COVID-19 Management

COVID-19-Triggered Acute Exacerbation of IPF, an Underdiagnosed Clinical Entity With Two-Peaked Respiratory Failure: A Case Report and Literature Review

Janus Kinase Inhibitors and Coronavirus Disease (COVID)-19: Rationale, Clinical Evidence and Safety Issues

Contact Info

Product

Resources

About